MONOGRAPH OF HYPERTONIC HEART DISEASE CONTENTS HYPERTONIC HEART DISEASE 1.1. HYPERTONIC HEART DISEASE AS AN AUTONOMOUS CLINICAL ENTITY WITH A NEW MEANING
The new meaning behind the concept of hypertonic heart disease
The change in the concept of hypertonic heart disease
– New meaning due to the better understanding of the
complex clinical picture of hypertonic heart disease
1.2. EPIDEMIOLOGY OF HYPERTONIC HEART DISEASE
Cardiovascular diseases and hypertension
Epidemiological data on hypertension – age, gender, geographical distribution,
Relationship between hypertension and metabolic syndrome
Relationship between hypertension and diabetes mellitus
1.3. PHARMACOLOGY OF HYPERTONIC HEART DISEASE
The principles of chronotherapy for hypertonic heart disease
Significance of circadian rhythm in cardiovascular diseases
Chronopharmacodynamics of conventional antihypertensive treatment
Chronopharmacodynamics of calcium antagonists
Chronopharmacodynamics of angiotensin-converting enzyme inhibitors (ACEIs)
Chronopharmacodynamics of alpha-adrenoceptor antagonists
Chronopharmacodynamics of beta-adrenoceptor antagonists
Chronopharmacodynamics of angiotensin II receptor blockers (ARBs)
Aspirin and the chronopharmacodynamics of antihypertensive treatment
Chronotherapy for resistant high blood pressure
Chronotherapy for (hypertonic) ischaemic heart disease
Interactions between medications used for the treatment of hypertonic heart diease
The role of genetic factors in interactions with the body
Cardiovascular medication – food interactions
Foodstuffs with high fat and oil contents
Aims of the therapy of hypertonic heart diease
Efficacy of blood pressure lowering treatment
Aspects of choosing medications for the treatment of hypertonic heart disease
The role of doctor’s care in improving patients’ quality of life
The role of pharmaceutical care in the prevention and treatment of hypertonic heart disease
Pharmaceutical care program for hypertonic heart disease
Main objectives of pharmaceutical care in the field of hypertonic heart disease
CARDIOLOGIC ASPECTS OF HYPERTONIC HEART DISEASE 2.1. THE CARDIOLOGIC ASPECTS OF HYPERTENSION
Hypertension and ischaemic heart disease
Impact of antihypertensive medication on cardiovascular risk
Angiotensin-converting enzyme inhibitors (ACE-inhibitors)
Cardiologic approach during examination and treatment of hypertonic patients
2.2. CARDIAC FAILURE
The treatment of heart failure in practice
Monitoring and management of heart failure patients, importance of heart failure centers
2.3. HYPERTONIC ISCHAEMIC HEART DISEASE, MICROVASCULAR ANGINA PECTORIS
Hypertonic ischaemic heart disease, a novel concept
Anatomy of the coronary microvasculature
Intercapillary and dffusion distance and their significance
Blood supply of the cardiac muscle, with special regard to the microvascular coronary circulation
The renin-angiotensin-aldosterone system (RAAS)
Role of adrenergic receptors in hypertonic ischaemic heart disease
Impact of hormonal regulation on hypertonic ischaemic heart disease
Epidemiology and prevalence of hypertonic ischaemic heart disease
Justification for the use of the term „women’s ischaemic heart disease”
Role of risk factors in hypertonic ischaemic heart disease
Risk assessment using traditional risk factors and scoring
New risk factors and their role in women’s ischaemic heart disease
Evaluation of symptoms and the prevalence of ischaemia, gender differences
Pathophysiology of hypertonic heart disease and consequent myocardial ischaemia
An overview of pathophysiologic factors of hypertonic heart diease
Factors influenced by non-pharmacological and pharmacological treatment
Changes in coronary reactivity, gender differences
New term for women’s ischaemic heart disease: microvascular angina pectoris
General prognosis of women’s ischaemic heart disease
Prognosis of non-obstructive coronary disease
Factors influencing the risk of ischaemic heart disease in women
Hypertonic heart disease and cardiac syndrome X
Diagnosis of hypertension induced ischaemic heart disease
Characteristics of hypertension induced angina decubitus
Characteristics of hypertension induced effort angina pectoris
Other symptoms of hypertension induced angina pectoris
Physical diagnostics of hypertension induced angina
Overview of instrumental diagnostics of hypertension induced ischaemic heart disease (angina
Non-invasive examination of atherosclerosis
Radiologic and nuclear cardiology techniques
Concurrent 24 hour blood pressure and ECG monitoring
Treatment of microvascular coronary disease
2.3.30.2.5. Thrombocyte aggregation inhibitors
Treatment of women’s ischaemic heart disease
Principles of pharmaceutical treatment of women’s ischaemic heart disease
Treatment of ischaemic heart disease and non-obstructive coronary disease in women
2.4. NEW METHOD FOR THE STAGING OF HYPERTONIC HEART DISEASE: MULTIFACTORIAL ECHOCARDIOGRAPHIC ASSESSMENT
Definition of hypertonic heart disease and its new concept
Principles, significance and necessity of hypertonic heart disease staging
Short overview of the clinical forms of hypertonic heart diease diagnosable by echocardiography
Clinical processes diagnosable by echocardiography
Heart muscle ischaemia, microvascular coronary disease, cardiac syndrome X
Development of cardial complications detected by echocardiography and their estimated duration in
Hypertonic heart disease and its staging using multifactorial echocardiographic assessment
General therapy principles for all disease stages
2.5. ASSESSMENT OF LEFT VENTRICULAR HYPERTROPHY BY ECHOCARDIOGRAPHIC METHODS
Nosology of left ventricular hypertrophy
Conditions causing left ventricular hypertrophy
Measurements to ascertain/stage hypertrophy
2.6. ISCHAEMIC HEART DISEASE, ECHOCARDIOGRAPHY
Role of echocardiography in ischaemic heart disease and hypertension
Real-time 3-dimensional echocardiography
Three-dimensional „speckle tracking”
2.7. ECG ABNORMALITIES DETECTED IN HYPERTONIC DISEASE
Theoretical approach to ECG abnormalities
ECG abnormalities detected in hypertonic disease
ECG signs of left ventricular hypertrophy
Duration of the QRS and the time of the onset of the intrinsiciod deflection
ST-segment and T-wave abnormalities (secondary repolarization abnormalities)
Indices used to assess left ventricular hypertrophy
Romhilt-Estes point score system for the characterization of left ventricular hypertrophy
Other ECG phenomena related to left ventricular hyperthrophy
2.7.2.4.4.1. Increased left ventricular systolic pressure
2.7.2.4.4.2. Cardiac conduction abnormalities
2.7.2.4.4.3. Left anterior fascicular block
2.7.2.4.4.4. Ventricular ectopics, sudden death
2.7.2.4.4.5. Signs of increased left ventricular pressure. Atrial fibrillation
Problems with the ECG criteria for left ventricular hypertrophy
Left ventricular hypertrophy detected by ECG is a sign of cardiovascular events
2.8. CARDIAC ABNORMALITIES IN HYPERTENSION – RADIOLOGY – ISOTOPE DIAGNOSTICS
Significance of MR (magnetic resonance) imaging in left ventricular hypertrophy (2)
Determination of regional left ventricular function
Significance (role) of nuclear cardiology in hypertonic heart disease
Nuclear cardiology (isotope diagnostic) methods in hypertension induced heart disease
2.8.3.2.1.1. Myocardial perfusion stress test
2.8.3.2.1.2. Examinations using radiopharmaceuticals for myocardial SPECT imaging
Quantitative analysis of myocardial perfusion by PET, detection of heart muscle viability using PET
PET (Positron emission tomography) myocardial perfusion imaging
PET- (SPECT) imaging of myocardial viability and metabolism
Indications of MUGA scan in congestive cardiomyopathy
Evaluation cardiac sympathetic innervation
Practical and diagnostic value of nuclear cardiology methods in hypertonic heart disease
Detection of left ventricular hypertrophy – determination of the ventricular wall
Diastolic and systolic funtion impairment
Detection of ischaemia and necrosis induced by coronary microvascular disease
Detection of myocardial ischaemia and necrosis induced by coronary sclerosis
Forecasting of dangerous ventricular arrhythmia
Determination of left ventricular dilatation
MULTIDISCIPLINAR ASPECTS OF HYPERTONIC HEART DISEASE 3.1. DIABETOLOGIC ASPECTS OF HYPERTONIC HEART DISEASE
Aggravating role of impaired nitrogen-monoxide (NO) metabolism
Effect of the dysfunction of the G-protein coupled receptor signaling system
Role of the increased activity of the renin-angiotensin system
Increased activity of the renin-angiotensin system
The most significant factors often accompanying or influencing diabetic, hypertonic heart disease
Effects of clinically barely detectable, low-grade tissue inflammation
3.2. LIPIDOLOGIC APPREACH TO HYPERTONIC HEART DISEASE
Significance of simultaneous treatment of hypertension and dyslipidaemia
Endothelial dysfuncion and atherosclerosis caused by hypertension and high cholesterol levels
Clinical gain from the treatment of dyslipidemia
Significance of postprandial trigliyeride levels
Reducing inflammation, the JUPITER analysis
Lipidologic aspects of microvascular angina
Lipidologic and anti-atherosclerotic effects of blood pressure lowering
Lipid-modulating effects of antihypertensive drugs
Anti-atherosclerotic effect of calcium antagonists
Simultaneous administration of statin and blood pressure lowering drugs
Side effects and monitoring of statin treatment
3.3. ENDOCRINE ASPECTS OF HYPERTONIC HEART DISEASE
Relationship of cardiovascular damage and endocrine hypertension
Essential hypertension – endocrine (secondary) hypertension
Therapeutic principles and possibilities in the treatment of endocrine hypertension
3.4. ANGIOLOGIC ASPECTS OF HYPERTONIC HEART DISEASE
Relationship of hypertension and vascular abnormalities
Hypertension and microvascular dysfunction
3.5. HYPERTONIC HEART DISEASE AND RENAL DISEASE 3.6. HYPERTONIC HEART DISEASE AND SPORTS
Role of regular exercise int he prevention and treatment of hypertension
Characteristics of the athlete’s heart
Regular exercise and hypertonic heart diseases
Physiological and pathological left ventricular hypertrophy
The role of regular exercise in the prevention of other hypertonic heart diseases
Who benefits from regular physical exercise?
How much and what kind of exercise may be recommended?
Pharmaceutical treatment of hypertension and sport
GENERAL PRACTICE ASPECTS OF HYPERTONIC HEART DISEASE 4.1. HYPERTONIC HEART DISEASE FROM THE GENERAL PRACTITIONER’S POINT OF VIEW IN FAMILY PRACTICE
Incidence of hypertension and hypertonic ischaemic heart disease
Important and indispensable basic terms of hypertension
Normal and pathological blood pressure levels and the definition of hypertension
Ambulatory blood pressure monitoring (ABPM)
4.1.2.1.3.1. Possible indications of ABPM measurement
Limits of general practitioner’s competency
List of general practice competencies, limits of competency
Special characteristics of hypertonic heart disease
Treatment of hypertonic ischaemic heart disease and heart failure
Treatment choices in ischaemic heart disease
4.1.6.1.1.1. Indications of ACE-inhibitor therapy in heart failure
4.1.6.1.10. Beta-adrenoceptor antagonists
Patient education: educating people about health and diseases
Arbeiten mit Textvariablen Textvariablen in Tabellen Variablen können in der Länge begrenzt werden, z.B. bedeutet $Vorname;13#, dass Vornamen, die länger als 13 Zeichen sind, ab der 14. Stelle abgeschnitten werden. Diese Variante ist wichtig für Textvorlagen, die per SMS verschickt werden, da hier nur begrenzte Textlängen möglich sind. Formatierung der Textvariablen Die Format
NOTA INFORMATIVA IMPORTANTE CONCORDATA CON L’AGENZIA ITALIANA DEL FARMACO (AIFA) Comunicazione diretta agli operatori sanitari su Lariam (meflochina) per la chemioprofilassi della malaria e rischio di reazioni avverse neuropsichiatriche. Lariam® (meflochina) può indurre disordini neuropsichiatrici potenzialmente gravi. Le più comuni reazioni neuropsichiatriche alla mefloc